Eckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from the European Defense Fund for Development of Medical Countermeasures^DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Schlagwort(e):VertragEckert & Ziegler Affiliate to Receive Multi-Million Euro Grant from theEuropean Defense Fund for Development of Medical Countermeasures04.08.2022 / 10:07Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.---------------------------------------------------------------------------BERLIN, GERMANY, August 04, 2022 - Myelo Therapeutics GmbH, an Affiliate ofEckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX)and member of a pan-European consortium of research and industry partners,was selected to receive grants worth approximately 17 million Euro for thedevelopment of its medical countermeasure (MCM) against acute radiationsyndrome. The current program has the potential to advance its MCM candidatetowards a marketing authorization application at the end of the four-yearfunding period.Myelo Therapeutics international team, which started 2019 its countermeasureprogram with the support of the U.S. National Institute of Allergy andInfectious Diseases (NIAID), part of the National Institutes of Health, isuniquely positioned to establish a comprehensive research network anddevelop novel countermeasures for deployment in EU and NATO territory.Beyond its potential as a medical countermeasure, the MCM portfolio hasseveral promising clinical applications in mitigating radiation andchemotherapy-induced toxicity in nuclear medicine and (radiation) oncology.The funds are part of a 49 million EUR grant that the European Defense Fundintends to allocate to the consortium led by the French Commissariat àl'Energie Atomique et aux Energies Alternatives (CEA), a group that isworking on military medical countermeasures (MCMs) against ChemicalBiological Radiological and Nuclear (CRBN) threats. The project "Europeanagile network for medical COUNTERmeasures Against CBRN Threats" (COUNTERACT)aims to establish a robust and agile network within the EU to be capable ofdeveloping and deploying medical countermeasures (MCMs) against majorChemical, Biological, Radiological, and Nuclear (CRBN) threats such asterror plots, nuclear accidents, weapon development and epidemics caused byemerging or re-emerging high consequence pathogens. COUNTERACT will increaseEU preparedness for immediate response to such threats.About Myelo Therapeutics: Myelo Therapeutics GmbH is a pharmaceuticalcompany based in Berlin, Germany, developing innovative medicalcountermeasure treatments against Chemical, Biological, Radiological, andNuclear (CRBN) threats and Supportive Care therapies in Oncology and NuclearMedicine. For more information, visit www.myelotherapeutics.com.About Eckert & Ziegler: Eckert & Ziegler Strahlen- und Medizintechnik AGwith its 900 employees, is a leading global specialist for isotope-relatedapplications in nuclear medicine, industry, and radiation therapy. Thecompany offers a broad range of services and products along the radioactivevalue chain, from early development work to contract manufacturing anddistribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in theSDAX index of Deutsche Börse.About Acute Radiation Syndrome: ARS, also known as radiation toxicity orradiation sickness, is an acute illness that presents after exposure oflarge portions of the body to high levels of radiation, like those thatmight be experienced during a radiological/nuclear incident or attack. Theprimary manifestation of ARS is the depletion of hematopoietic stem andprogenitor cells, constituting one of the major causes of mortality.Contact:Eckert & Ziegler AGKarolin Riehle, Investor RelationsRobert-Rössle-Str. 10, 13125 Berlin, GermanyTel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de; www.ezag.com---------------------------------------------------------------------------04.08.2022 Veröffentlichung einer Corporate News/Finanznachricht,übermittelt durch DGAP - ein Service der EQS Group AG.Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten,Corporate News/Finanznachrichten und Pressemitteilungen.Medienarchiv unter http://www.dgap.de--------------------------------------------------------------------------- Sprache: Deutsch Unternehmen: Eckert & Ziegler Strahlenund Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Deutschland Telefon: +49 30 941084-138 Fax: +49 30 941084-112 E-Mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Indizes: SDAX Börsen: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart, Tradegate Exchange EQS News ID: 1413225Ende der Mitteilung DGAP News-Service---------------------------------------------------------------------------1413225 04.08.2022°